HDFC Securities Pick of the Week 27th Apr'26: Supriya Lifescience Ltd

Supriya Lifescience Ltd. is a niche-focused API manufacturer with a differentiated portfolio of 40 APIs across multiple therapeutic segments, characterized by limited competition. The company is India’s largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride, and among the largest exporters of Salbutamol Sulphate. It serves 1,500+ customers across 120+ countries, with a strong presence in regulated markets.

Europe has emerged as a key growth driver, contributing 38% of sales in 9MFY26, while the US business, currently ~5% of revenue, has been growing steadily and is expected to scale meaningfully over the next 2-3 years. Revenue concentration remains moderate, with 58% of revenue from the top 10 customers.

Supriya operates five manufacturing blocks with a reactor capacity of 932 KLPD, supported by deep backward integration, enabling best-in-class EBITDA margins of 33-35%. Regulatory capabilities include 21 US FDA DMFs filed and 11 CEPs granted as of December 2025.

The company has delivered ~20% revenue CAGR over the past three years and targets ₹1,000 crore revenue by FY27, followed by a doubling to ₹2,000 crore in 4-5 years. Growth drivers include capacity expansion, new API launches, and entry into CMO/CDMO, highlighted by a 10-year exclusive CDMO contract with DSM‑Firmenich, expected to add ₹60-70 crore annual revenue from FY28.

Download the Full Report: Click Here